Roundtable Discussion: Iams Considers Platinum Rechallenge or Other Therapy for Relapsed ES-SCLC
September 22nd 2022During a Targeted Oncology case-based roundtable event, Wade T. Iams, MD, discussed the case of a patient who progressed following a partial response to platinum-based chemotherapy for extensive-stage small cell lung cancer.
Latest Recommendations for Broad Molecular Testing in Advanced NSCLC
September 14th 2022During a live virtual event, Zofia Piotrowska, MD, MHS, discussed the National Comprehensive Cancer Network guidelines for molecular testing for a patient with advanced non–small cell lung cancer, and how to approach a patient who is found to have an EGFR exon 20 insertion. This is the first of 2 articles based on this event.
POLL: What Frontline Treatment Would You Choose for Favorable- and Intermediate-Risk RCC?
August 29th 2022Participants of a live, virtual case-based event discussed different scenarios for treatment of a patient with previously untreated clear cell renal cell carcinoma. Vote in the polls on what you would have chosen if this was your patient.
Roundtable Discussion: Kandra Explores Benefit of Chemoimmunotherapy for Small Cell Lung Cancer
August 28th 2022During a Targeted Oncology case-based roundtable event, Ajay Kandra, MD, discussed with participants the challenges and treatment options for a patient with extensive-stage small cell lung cancer.
Roundtable Discussion: Abou-Alfa Evaluates Choice of Therapy for HCC Based on Patient Factors
August 25th 2022During a Targeted Oncology case-based roundtable event, Ghassan K. Abou-Alfa, MD, MBA, discussed the case of a patient with hepatocellular carcinoma whose comorbidities impacted the choice of treatment.
Hutson Walks Through Updates in the Management of Clear Cell RCC
August 23rd 2022During a Targeted Oncology case-based roundtable event, Thomas Hutson, DO, PharmD, discussed the most recent data supporting immune checkpoint inhibitor plus tyrosine kinase inhibitor combinations for frontline treatment of patients with renal cell carcinoma.
Treating mCSPC with Anti-Androgen Therapy and Monitoring for Progression
August 17th 2022During a live virtual event, Roby A. Thomas, MD, discussed the tolerability of androgen receptor therapy and personal experiences with treatment of patients with metastatic castration-sensitive prostate cancer. This is the second of 2 articles based on this event.
Exploring Sacituzumab Govitecan and Other Second-Line TNBC Therapies
August 15th 2022During a live virtual event, Elizabeth Ann Mittendorf, MD, PhD, discussed the case of a patient with triple-negative breast cancer whose disease progressed following adjuvant dose-dense doxorubicin plus cyclophosphamide with paclitaxel, then frontline gemcitabine and carboplatin. This is the second of 2 articles based on this live event.
Results of Amivantamab and Mobocertinib Trials Evaluated for Use in NSCLC
August 3rd 2022During a Targeted Oncology case-based roundtable event, Christine Bestvina, MD, discussed the outcomes of clinical trials of the EGFR exon 20-targeted agents amivantamab and mobocertinib with participants. This is the second of 2 articles based on this event.
Treating Multiple Myeloma Following Quadruplet Induction Therapy and ASCT
August 1st 2022During a Targeted Oncology live virtual event, Caitlin Costello, MD, discussed treatment of a patient who previously received systemic therapy and autologous stem cell transplant for multiple myeloma. This is the second of 2 articles based on this event.